Skip to main content
. 2023 Jan 18;123(4):464–477. doi: 10.1055/a-1988-5047

Fig. 3.

Fig. 3

12-Month incidence of the primary (efficacy) endpoint, which was a composite of death, myocardial infarction, and stroke, in patients assigned to ticagrelor and prasugrel in quartile 1 ( A ), 2 ( B ), 3 ( C ), and 4 ( D ) of platelet count.